SynthesisJournal of thrombosis and thrombolysis2025
Incidence of thrombosis in patients with hepatocellular carcinoma: systematic review and meta-analysis.
Synthesis in Journal of thrombosis and thrombolysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a major global health concern, associated with substantial morbidity and mortality. Thrombosis, including venous thromboembolism, deep vein thrombosis, and portal vein thrombosis, further exacerbates the clinical burden in liver cancer patients. However, the incidence rate thrombosis in this population remains incompletely estimated. The main aim of systematic review and meta-analysis is estimating the incidence of thrombotic events in patients with liver cancer.
methodsWe conducted a comprehensive search of databases, including PubMed, Scopus, Web of Science, and Embase, for studies (from inception to January 30, 2025) reporting thrombotic events in liver cancer patients. Pooled estimates of thrombosis incidence were calculated using random effect models, and subgroup analyses were performed based on the follow-up periods and presence of cirrhosis with HCC versus HCC alone.
resultsA total of 24 studies comprising 935,639 liver cancer patients were included in the analysis. The pooled incidence of thrombotic events in liver cancer patients was 35.85 per 1,000 patients (95% CI: 24.49–52.47). The incidence rate varied by follow-up period, with rates of 28.99 (95% CI: 11.34–74.4), 21.16 (95% CI: 9.96–44.93), and 47.19 (95% CI: 22.16–98.19) for 6-month, 12-month, and > 12-month follow-ups, respectively. The incidence in patients with cirrhosis and HCC was higher than those with HCC alone: 229.56 per 1,000 patients (95% CI: 166.40–316.69) versus 26.61 per 10,000 patients (95% CI: 18.71–37.84), respectively.
conclusionPatients with HCC are at significant increased risk of thrombosis. This meta-analysis highlights the importance of monitoring thrombotic risk in liver cancer management. Future research should focus on targeted prevention and treatment strategies to reduce thromboembolic complications in this high-risk population.
Indexed as
Identifiers
40616642What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.